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382 Quantifying publication bias in cystic ﬁbrosis clinical trials
M.N. Hurley1,2, A.P. Prayle1,2, A. Smyth1,2,3. 1University of Nottingham, Child
Health, Nottingham, United Kingdom; 2Nottingham Respiratory Biomedical
Research Unit, Nottingham, United Kingdom; 3Trent Local Research Network,
Nottingham, United Kingdom
Background: The practice of evidence-based medicine depends upon the publica-
tion of high quality clinical studies. However, publication bias may act to exclude
some trials from contributing to the knowledge base. The inﬂuence of such biases
upon the evidence base is often unknown as clinicians have no way of knowing the
results of unreported studies. ClinicalTrials.gov was commissioned in 2000. In 2005
the ICMJE announced that publication of trials would be limited to trials registered
with a public registry prior to commencing.
Aim: We aimed to quantify reporting biases present within the CF literature.
Method: We interrogated ClinicalTrials.gov using ‘cystic ﬁbrosis’ as the keyword,
limited to interventional studies that had been closed. We searched PubMed, the
Cochrane Central Register of Controlled Trials and Google Scholar for publications
using ClinicalTrials.gov ID, study title and Chief Investigator name. We documented
publication date and study sponsor. A survival analysis was performed using
R (version 2.12.1).
Results: In total 142 studies were identiﬁed (completed 1998–2010) of which 59
were published. Median time to publication was 2.09 years.
Proportion published by end of year
Year Proportion of studies published at the end of each year following completion,
after taking into account right censored studies
1 6.7%
2 24.5%
3 47.9%
4 56.6%
5 59.0%
We performed a similar survival analysis with categories of sponsor as subgroups.
Conclusion: The publication of results of clinical trials, which contribute to the
evidence base on which clinicians depend, are often delayed.
383 Upper airway pathology in children with cystic ﬁbrosis (CF)
I. Martynova1, E. Karpova2, N. Kapranov3. 1Filatov Chidren’s City Clinical
Hospital N13, Moscow, Russian Federation; 2Chidren’s Clinical Hospital N7,
Moscow, Russian Federation; 3Reseach Center for Medical Genetics RAMS, Cystic
Fibrosis, Moscow, Russian Federation
Upper airway (UAW) pathology in CF has been neglected and can be a source of
bacterial infections of lower airway, and signiﬁcantly decrease the quality of patients
life.
Objectives: To study the frequency of chronic rhinosinusitis (CRS) in children with
CF, correlation of genotype and ENT disorders and effectiveness of dornase alfa
[inhaled via a special nebulizer (PARI SINUS™)].
Methods: The study included 103 patients with CF (48 boys and 55 girls) aged
from 1 to 17 years. 14 children received a 1-year dornase alfa, twice a day at a
dose of 2.5mg. Special functional diagnostic of ENT were nasal endoscopy and
CT scan.
Conclusion: CRS was diagnosed in 83 patients (82% of total), in which 56 pa-
tients (68%) − with nasal polyps. Predominant clinical signs were chronic nasal
congestion, recurrent rhinitis in 83 (100%), rhinorrhoea in 53 (64%), mouth
breathing, anosmia in 19 (23%), facial pain in 15 children (18%). Severe disease of
Shwachman score was observed in 36 out of 103 patients (35%), all of them were
with nasal polyps and delF508 mutations. All children without CRS (20 patients)
belonged to the younger age group (up to 3 years). The treatment of dornase alfa
revealed signiﬁcant improvement in nasal breathing and reduction of polyps of
investigated group.
384 Pregnancy and motherhood in women with cystic ﬁbrosis:
experience and outcomes in a regional adult UK centre
C. Etherington1, D. Peckham1, S. Conway1, I. Clifton2. 1Regional Adult CF Unit,
St James’s University Hospital, Leeds, United Kingdom; 2Respiratory Department,
St James’s University Hospital, Leeds, United Kingdom
As the median survival for CF continues to improve more women face decisions
regarding pregnancy. The aim of this study was to review the experience of
pregnancy and assess both maternal and fetal outcomes.
A retrospective review of the case notes of women who became pregnant between
1990 and 2009 was performed. Maternal lung function, weight, number of clinic
visits and days of intravenous antibiotics were recorded for 4 years pre pregnancy,
during pregnancy and 4 years post pregnancy.
35 women (median age 24 yrs, FEV1 62% and BMI 20.9) became pregnant
and delivered 50 children. 13 had pre-existing CFRD and 6 women developed
gestational diabetes. Median (range) maternal weight gain during pregnancy was
6.5 kg (−2.9 to 15.3 kg). There was a signiﬁcant increase in number of clinic visits
(p = 0.009) and requirement for iv antibiotics during pregnancy and up to 2 yrs post
delivery (p = 0.013). Women with CFRD had lower weight gain during pregnancy
(5.3 vs. 6.8 kg, p = 0.024), lower birth weight babies (2.1 vs. 2.96 kg, p = 0.002)
and shorter gestation (34 vs. 37 weeks, p = 0.001). A prepregnancy FEV1 less
than 60% predicted was associated with lower maternal weight during pregnancy
(49.9 vs. 59.4 kg, p = 0.04), shorter gestation (34 vs. 36 weeks, p = 0.018), lower
birth weight (2.35 vs. 2.67 kg, p = 0.022) and a signiﬁcant decline in FEV1 post
pregnancy (p = 0.03). Seven women died post pregnancy.
The course of pregnancy cannot be predicted in any individual and all women should
anticipate more intensive antepartum and postpartum treatment. The presence of
pre-existing CFRD and a prepregnancy FEV1 of <60% predicted are associated
with signiﬁcantly worse outcomes.
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Introduction: As young adults living with a chronic respiratory illness, cystic
ﬁbrosis (CF) patients are more prone to the harmful effects of tobacco smoke,
excessive alcohol and recreational drugs. We wished to look at the prevalence of
smoking, drugs and alcohol use in our cohort of adult CF patients.
Methods: Using a structured questionnaire, we surveyed 98 consecutive CF patients
(mean age 28 yrs [range 18−66], 49 female) attending our large adult CF unit
looking at smoking, alcohol, and recreational drug use.
Results: Although 80% had never smoked tobacco, 8% were ex-regular smokers
(average 7.8 pack-yrs [range 2−16]), 4% were regular smokers, 5% were occasional
(not daily) smokers, and 3% smoked rarely. Only 2% of the smokers had used some
form of aid to try to quit. 86% took alcohol, with 66% using it less than once a
week but 33% more frequently (average 15 units per week [range 1−40]). Only
1 patient had attended a formal rehabilitation programme for excessive drinking.
Finally, with respect to recreational drug use, 13% had ever used drugs and 3% took
drugs at least once a week (the commonest being cannabis, followed by LSD and
cocaine). None had attended any rehabilitation programme.
Conclusion: Smoking, excessive alcohol and recreational drug use is a real problem
among the adult CF population and it is important that these issues are discussed and
explored at periodic reviews within the CF team to identify patients who are most
vulnerable. The long-term deleterious impact of unhealthy life choices should be
reiterated at every opportunity to high-risk patients, and adequate facilities should
be made available to those who want help to deal with these habits.
